| Efficacy and safety of once-weekly semaglutide 2· 0 mg versus 1· 0 mg in patients with type 2 diabetes (SUSTAIN FORTE): a double-blind, randomised, phase 3B trial JP Frías, P Auerbach, HS Bajaj, Y Fukushima, I Lingvay, S Macura, ... The Lancet Diabetes & Endocrinology 9 (9), 563-574, 2021 | 120 | 2021 |
| Efficacy and safety of co-administered once-weekly cagrilintide 2· 4 mg with once-weekly semaglutide 2· 4 mg in type 2 diabetes: a multicentre, randomised, double-blind, active … JP Frias, S Deenadayalan, L Erichsen, FK Knop, I Lingvay, S Macura, ... The Lancet 402 (10403), 720-730, 2023 | 81 | 2023 |
| Twice‐daily insulin degludec/insulin aspart provides superior fasting plasma glucose control and a reduced rate of hypoglycaemia compared with biphasic insulin aspart 30 in … E Franek, M Haluzík, S Canecki Varžić, M Sargin, S Macura, J Zacho, ... Diabetic Medicine 33 (4), 497-505, 2016 | 56 | 2016 |
| Superior weight loss with once-weekly semaglutide versus other glucagon-like peptide-1 receptor agonists is independent of gastrointestinal adverse events I Lingvay, T Hansen, S Macura, M Marre, MA Nauck, R De La Rosa, ... BMJ Open Diabetes Research and Care 8 (2), e001706, 2020 | 48 | 2020 |
| Impact of baseline characteristics and beta‐cell function on the efficacy and safety of subcutaneous once‐weekly semaglutide: a patient‐level, pooled analysis of the SUSTAIN 1 … VR Aroda, MS Capehorn, L Chaykin, JP Frias, NL Lausvig, S Macura, ... Diabetes, Obesity and Metabolism 22 (3), 303-314, 2020 | 18 | 2020 |
| Insulin degludec/insulin aspart once daily in Type 2 diabetes: a comparison of simple or stepwise titration algorithms (BOOST®: SIMPLE USE) SW Park, WMW Bebakar, PG Hernandez, S Macura, ML Hersløv, ... Diabetic Medicine 34 (2), 174-179, 2017 | 16 | 2017 |
| Treatment intensification with insulin degludec/insulin aspart twice daily: randomized study to compare simple and step-wise titration algorithms G Gerety, WMW Bebakar, L Chaykin, M Ozkaya, S Macura, ML Hersløv, ... Endocrine Practice 22 (5), 546-554, 2016 | 13 | 2016 |
| IDegAsp provides superior FPG control and reduced hypoglycaemia vs BIAsp 30 in insulin-naive adults with type 2 diabetes: a randomised phase 3 trial E Franek, M Haluzík, SC Varzic, M Sargin, S Macura, J Zacho, ... Diabetologia 57, S380-S380, 2014 | 10 | 2014 |
| Insulin degludec/insulin aspart (IDegAsp) provides superior FPG control and reduced hypoglycaemia vs. biphasic insulin aspart 30 (BIAsp 30) in insulin-naive adults with type 2 … E Franek, M Haluzik, S Canecki-Varzic, M Sargin, S Macura, J Zacho, ... Diabetes 63, A225-A225, 2014 | 4 | 2014 |
| 1668-P: Novel Once-Weekly Amylin Analog Petrelintide (ZP8396) Is Well Tolerated with Improved GI Tolerability after Multiple Dosing JON GRIFFIN, U HÖVELMANN, AE MELGAARD, S MACURA, ... Diabetes 73 (Supplement_1), 2024 | | 2024 |
| 53-OR: Efficacy and Safety of Coadministered sc Semaglutide and sc Cagrilintide in Type 2 Diabetes JP FRIAS, S DEENADAYALAN, L ERICHSEN, FK KNOP, I LINGVAY, ... Diabetes 72 (Supplement_1), 2023 | | 2023 |
| Effect of once-weekly semaglutide 2 mg vs 1 mg on HbA (1c) and body weight by baseline demographic subgroups: SUSTAIN FORTE post hoc analysis JP Frias, L Bardtrum, Y Hansen, I Lingvay, S Macura, N Tentolouris, ... DIABETOLOGIA 65 (SUPPL 1), S289-S290, 2022 | | 2022 |
| Efficacy and Safety of Once-Weekly Semaglutide 2.0 mg vs. 1.0 mg by Baseline HbA1c and BMI: SUSTAIN FORTE Subgroup Analyses JB Buse, P Auerbach, HS Bajaj, Y Fukushima, I Lingvay, S Macura, ... Diabetologie und Stoffwechsel 17 (S 01), P 012, 2022 | | 2022 |
| Efficacy and Safety of Once-Weekly Semaglutide 2.0 mg vs 1.0 mg by Baseline HbA1c and BMI: SUSTAIN FORTE Subgroup Analyses B John, P Auerbach, H Bajaj, Y Fukushima, I Lingvay, S Macura, ... Canadian Journal of Diabetes 45 (7), S15-S16, 2021 | | 2021 |
| 665-P: Efficacy and Safety of Once-Weekly Semaglutide 2.0 mg vs. 1.0 mg by Baseline HbA1c and BMI: SUSTAIN FORTE Subgroup Analyses JB Buse, P Auerbach, HS Bajaj, Y Fukushima, I Lingvay, S Macura, ... Diabetes 70 (Supplement_1), 2021 | | 2021 |
| 101-OR: Efficacy and Safety of Once-Weekly Semaglutide 2.0 vs. 1.0 mg for Type 2 Diabetes: SUSTAIN FORTE Randomized Trial JP Frias, P Auerbach, HS Bajaj, Y Fukushima, I Lingvay, S Macura, ... Diabetes 70 (Supplement_1), 2021 | | 2021 |
| PO231 IDEGASP PROVIDES SUPERIOR FPG CONTROL AND REDUCED HYPOGLYCEMIA VS BIASP 30 IN INSULIN-NAIVE ADULTS WITH TYPE 2 DIABETES: A RANDOMIZED PHASE 3 TRIAL E Franek, M Haluzik, S Canecki-Varzic, M Sargin, S Macura, J Zacho, ... Diabetes Research and Clinical Practice 106, S166-S167, 2014 | | 2014 |
